메뉴 건너뛰기
Biochemia Medica
Volumn 23, Issue 2, 2013, Pages 154-171
Pharmacogenetics and personalized treatment of type 2 diabetes
Author keywords

Oral antidiabetic drugs; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Type 2 diabetes mellitus
Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BIGUANIDE DERIVATIVE; CYTOCHROME P450; GLIBENCLAMIDE; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR SUBSTRATE 1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MEGLITINIDE; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;
EID: 84878756560     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2013.020     Document Type: Review
Times cited : (43)
References (124)
  • 1
    • 82955247909 scopus 로고    scopus 로고
    • IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
    • Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21. http://dx.doi.org/10.1016/j.diabres.2011.10.029.
    • (2011) Diabetes Res Clin Pract , vol.94 , pp. 311-321
    • Whiting, D.R.1    Guariguata, L.2    Weil, C.3    Shaw, J.4
  • 2
    • 84867553855 scopus 로고    scopus 로고
    • Pharmacogenetics of P450 oxidoreductase: Implications in drug metabolism and therapy
    • Hu L, Zhuo W, He YJ, Zhou HH, Fan L. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenet Genomics 2012;22:812-9. http://dx.doi.org/10.1097/FPC.0b013e328358d92b.
    • (2012) Pharmacogenet Genomics , vol.22 , pp. 812-819
    • Hu, L.1    Zhuo, W.2    He, Y.J.3    Zhou, H.H.4    Fan, L.5
  • 3
    • 84857273073 scopus 로고    scopus 로고
    • Cytochrome P450 variations in different ethnic populations
    • McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8:371-82. http://dx.doi.org/10.1517/17425255.2012.657626.
    • (2012) Expert Opin Drug Metab Toxicol , vol.8 , pp. 371-382
    • McGraw, J.1    Waller, D.2
  • 4
    • 84873430927 scopus 로고    scopus 로고
    • Individualized therapy for type 2 diabetes: Clinical implications of pharmacogenetic data
    • Mannino GC, Sesti G. Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 2012;16:285-302. http://dx.doi.org/10.1007/s40291-012-0002-7.
    • (2012) Mol Diagn Ther , vol.16 , pp. 285-302
    • Mannino, G.C.1    Sesti, G.2
  • 5
    • 84872234822 scopus 로고    scopus 로고
    • Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms
    • Yoshida K, Maeda K, Sugiyama Y. Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms. Annu Rev Pharmacol Toxicol 2012; 53: 581-612. http://dx.doi.org/10.1146/annurev-pharmtox-011112-140309.
    • (2012) Annu Rev Pharmacol Toxicol , vol.53 , pp. 581-612
    • Yoshida, K.1    Maeda, K.2    Sugiyama, Y.3
  • 6
    • 84862076531 scopus 로고    scopus 로고
    • Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability -considerations for drug development
    • Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability -considerations for drug development. Expert Opin Drug Metab Toxicol 2012;8:723-43. http://dx.doi.org/10.1517/17425255.2012.678048.
    • (2012) Expert Opin Drug Metab Toxicol , vol.8 , pp. 723-743
    • Lai, Y.1    Varma, M.2    Feng, B.3    Stephens, J.C.4    Kimoto, E.5    El-Kattan, A.6
  • 7
    • 84864652235 scopus 로고    scopus 로고
    • Epigenetics: The missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes
    • Gilbert ER, Liu D. Epigenetics: the missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes. Epigenetics 2012;7:841-52. http://dx.doi.org/10.4161/epi.21238.
    • (2012) Epigenetics , vol.7 , pp. 841-852
    • Gilbert, E.R.1    Liu, D.2
  • 8
    • 77957259803 scopus 로고    scopus 로고
    • Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes
    • Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-7. http://dx.doi.org/10.1161/CIRCRESAHA.110.226357.
    • (2010) Circ Res , vol.107 , pp. 810-817
    • Zampetaki, A.1    Kiechl, S.2    Drozdov, I.3    Willeit, P.4    Mayr, U.5    Prokopi, M.6
  • 9
    • 84858433310 scopus 로고    scopus 로고
    • Personal omics profiling reveals dynamic molecular and medical phenotypes
    • Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Miriami E, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012;148:1293-307. http://dx.doi.org/10.1016/j.cell.2012.02.009.
    • (2012) Cell , vol.148 , pp. 1293-1307
    • Chen, R.1    Mias, G.I.2    Li-Pook-Than, J.3    Jiang, L.4    Lam, H.Y.5    Miriami, E.6
  • 10
    • 84866625627 scopus 로고    scopus 로고
    • Implementing personalized medicine: Development of a cost-effective customized pharmacogenetics genotyping array
    • Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012;92:437-9. http://dx.doi.org/10.1038/clpt.2012.125.
    • (2012) Clin Pharmacol Ther , vol.92 , pp. 437-439
    • Johnson, J.A.1    Burkley, B.M.2    Langaee, T.Y.3    Clare-Salzler, M.J.4    Klein, T.E.5    Altman, R.B.6
  • 11
    • 77956282569 scopus 로고    scopus 로고
    • The role of the KATP channel in glucose homeostasis in health and disease: More than meets the islet
    • McTaggart JS, Clark RH, Ashcroft FM. The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J Physiol 2010;588:3201-9. http://dx.doi.org/10.1113/jphysiol.2010.191767.
    • (2010) J Physiol , vol.588 , pp. 3201-3209
    • McTaggart, J.S.1    Clark, R.H.2    Ashcroft, F.M.3
  • 12
    • 59749094454 scopus 로고    scopus 로고
    • Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism
    • Flanagan SE, Clauin S, Bellanne-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2009;30:170-80. http://dx.doi.org/10.1002/humu.20838.
    • (2009) Hum Mutat , vol.30 , pp. 170-180
    • Flanagan, S.E.1    Clauin, S.2    Bellanne-Chantelot, C.3    de Lonlay, P.4    Harries, L.W.5    Gloyn, A.L.6
  • 13
    • 2342633204 scopus 로고    scopus 로고
    • Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes
    • Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-49. http://dx.doi.org/10.1056/NEJMoa032922.
    • (2004) N Engl J Med , vol.350 , pp. 1838-1849
    • Gloyn, A.L.1    Pearson, E.R.2    Antcliff, J.F.3    Proks, P.4    Bruining, G.J.5    Slingerland, A.S.6
  • 14
    • 33746686369 scopus 로고    scopus 로고
    • Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
    • Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-77. http://dx.doi.org/10.1056/NEJMoa061759.
    • (2006) N Engl J Med , vol.355 , pp. 467-477
    • Pearson, E.R.1    Flechtner, I.2    Njolstad, P.R.3    Malecki, M.T.4    Flanagan, S.E.5    Larkin, B.6
  • 15
    • 8744262895 scopus 로고    scopus 로고
    • Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2
    • Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004;89:5504-7. http://dx.doi.org/10.1210/jc.2004-1241.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 5504-5507
    • Zung, A.1    Glaser, B.2    Nimri, R.3    Zadik, Z.4
  • 16
    • 38449118682 scopus 로고    scopus 로고
    • Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study
    • Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, Charpentier G, et al. Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 2008;57:244-54. http://dx.doi.org/10.2337/db07-0615.
    • (2008) Diabetes , vol.57 , pp. 244-254
    • Vaxillaire, M.1    Veslot, J.2    Dina, C.3    Proenca, C.4    Cauchi, S.5    Charpentier, G.6
  • 17
    • 68449086849 scopus 로고    scopus 로고
    • The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population
    • Zhou D, Zhang D, Liu Y, Zhao T, Chen Z, Liu Z, et al. The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population. J Hum Genet 2009;54:433-5. http://dx.doi.org/10.1038/jhg.2009.54.
    • (2009) J Hum Genet , vol.54 , pp. 433-435
    • Zhou, D.1    Zhang, D.2    Liu, Y.3    Zhao, T.4    Chen, Z.5    Liu, Z.6
  • 18
    • 33744965950 scopus 로고    scopus 로고
    • The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
    • Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:2334-9. http://dx.doi.org/10.1210/jc.2005-2323.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 2334-2339
    • Sesti, G.1    Laratta, E.2    Cardellini, M.3    Andreozzi, F.4    Del Guerra, S.5    Irace, C.6
  • 19
    • 68049137605 scopus 로고    scopus 로고
    • Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance
    • Villareal DT, Koster JC, Robertson H, Akrouh A, Miyake K, Bell GI, et al. Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes 2009;58:1869-78. http://dx.doi.org/10.2337/db09-0025.
    • (2009) Diabetes , vol.58 , pp. 1869-1878
    • Villareal, D.T.1    Koster, J.C.2    Robertson, H.3    Akrouh, A.4    Miyake, K.5    Bell, G.I.6
  • 21
    • 83655172910 scopus 로고    scopus 로고
    • Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant
    • Siklar Z, Ellard S, Okulu E, Berberoglu M, Young E, Savas Erdeve S, et al. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant. J Pediatr Endocrinol Metab 2011;24:1077-80. http://dx.doi.org/10.1515/JPEM.2011.250.
    • (2011) J Pediatr Endocrinol Metab , vol.24 , pp. 1077-1080
    • Siklar, Z.1    Ellard, S.2    Okulu, E.3    Berberoglu, M.4    Young, E.5    Savas Erdeve, S.6
  • 22
    • 84861618060 scopus 로고    scopus 로고
    • Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: Transition from insulin to oral sulfonylureas
    • Dupont J, Pereira C, Medeira A, Duarte R, Ellard S, Sampaio L. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas. J Pediatr Endocrinol Metab 2012;25:367-70. http://dx.doi.org/10.1515/jpem-2011-0191.
    • (2012) J Pediatr Endocrinol Metab , vol.25 , pp. 367-370
    • Dupont, J.1    Pereira, C.2    Medeira, A.3    Duarte, R.4    Ellard, S.5    Sampaio, L.6
  • 23
    • 34547747922 scopus 로고    scopus 로고
    • Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects
    • Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 2007;81:375-82. http://dx.doi.org/10.1086/519174.
    • (2007) Am J Hum Genet , vol.81 , pp. 375-382
    • Ellard, S.1    Flanagan, S.E.2    Girard, C.A.3    Patch, A.M.4    Harries, L.W.5    Parrish, A.6
  • 24
    • 35148820198 scopus 로고    scopus 로고
    • Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period
    • Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S. Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab 2007;9 Suppl 2:28-39. http://dx.doi.org/10.1111/j.1463-1326.2007.00772.x
    • Diabetes Obes Metab 2007;9 Suppl , vol.2 , pp. 28-39
    • Patch, A.M.1    Flanagan, S.E.2    Boustred, C.3    Hattersley, A.T.4    Ellard, S.5
  • 25
    • 56149106823 scopus 로고    scopus 로고
    • Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients
    • Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008;31:1939-44. http://dx.doi.org/10.2337/dc07-2248.
    • (2008) Diabetes Care , vol.31 , pp. 1939-1944
    • Feng, Y.1    Mao, G.2    Ren, X.3    Xing, H.4    Tang, G.5    Li, Q.6
  • 26
    • 83755195416 scopus 로고    scopus 로고
    • The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes
    • author reply 9-10
    • Holstein JD, Kovacs P, Patzer O, Stumvoll M, Holstein A. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics 2012;13:5-7; author reply 9-10. http://dx.doi.org/10.2217/pgs.11.150.
    • (2012) Pharmacogenomics , vol.13 , pp. 5-7
    • Holstein, J.D.1    Kovacs, P.2    Patzer, O.3    Stumvoll, M.4    Holstein, A.5
  • 27
    • 78650321826 scopus 로고    scopus 로고
    • ABCC8 polymorphism (Ser1369Ala): Influence on severe hypoglycemia due to sulfonylureas
    • Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics 2010;11:1743-50. http://dx.doi.org/10.2217/pgs.10.135.
    • (2010) Pharmacogenomics , vol.11 , pp. 1743-1750
    • Sato, R.1    Watanabe, H.2    Genma, R.3    Takeuchi, M.4    Maekawa, M.5    Nakamura, H.6
  • 28
    • 70349131959 scopus 로고    scopus 로고
    • Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms
    • Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res 2009;40:387-92. http://dx.doi.org/10.1016/j.arcmed.2009.06.006.
    • (2009) Arch Med Res , vol.40 , pp. 387-392
    • Nikolac, N.1    Simundic, A.M.2    Katalinic, D.3    Topic, E.4    Cipak, A.5    Zjacic Rotkvic, V.6
  • 29
    • 84865674893 scopus 로고    scopus 로고
    • ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy
    • Nikolac N, Simundic AM, Saracevic A, Katalinic D. ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy. Genet Test Mol Biomarkers 2012;16:924-30. http://dx.doi.org/10.1089/gtmb.2011.0337.
    • (2012) Genet Test Mol Biomarkers , vol.16 , pp. 924-930
    • Nikolac, N.1    Simundic, A.M.2    Saracevic, A.3    Katalinic, D.4
  • 30
    • 0035370562 scopus 로고    scopus 로고
    • Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: A population study
    • Meirhaeghe A, Helbecque N, Cottel D, Arveiler D, Ruidavets JB, Haas B, et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet 2001;101:4-8. http://dx.doi.org/10.1002/ajmg.1297.
    • (2001) Am J Med Genet , vol.101 , pp. 4-8
    • Meirhaeghe, A.1    Helbecque, N.2    Cottel, D.3    Arveiler, D.4    Ruidavets, J.B.5    Haas, B.6
  • 31
    • 84555177674 scopus 로고    scopus 로고
    • The ATP-sensitive K(+) channel ABCC8 S1369A type 2 diabetes risk variant increases MgATPase activity
    • Fatehi M, Raja M, Carter C, Soliman D, Holt A, Light PE. The ATP-sensitive K(+) channel ABCC8 S1369A type 2 diabetes risk variant increases MgATPase activity. Diabetes 2012;61:241-9. http://dx.doi.org/10.2337/db11-0371.
    • (2012) Diabetes , vol.61 , pp. 241-249
    • Fatehi, M.1    Raja, M.2    Carter, C.3    Soliman, D.4    Holt, A.5    Light, P.E.6
  • 32
    • 85027917672 scopus 로고    scopus 로고
    • Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
    • Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenet Genomics 2012;22:206-14. http://dx.doi.org/10.1097/FPC.0b013e32835001e7.
    • (2012) Pharmacogenet Genomics , vol.22 , pp. 206-214
    • Lang, V.Y.1    Fatehi, M.2    Light, P.E.3
  • 33
    • 0033847575 scopus 로고    scopus 로고
    • Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: Evidence for pharmacogenetics in diabetes
    • Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000;17:543-5. http://dx.doi.org/10.1046/j.1464-5491.2000.00305.x.
    • (2000) Diabet Med , vol.17 , pp. 543-545
    • Pearson, E.R.1    Liddell, W.G.2    Shepherd, M.3    Corrall, R.J.4    Hattersley, A.T.5
  • 35
    • 2542460652 scopus 로고    scopus 로고
    • The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
    • Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004;27:1394-8. http://dx.doi.org/10.2337/diacare.27.6.1394.
    • (2004) Diabetes Care , vol.27 , pp. 1394-1398
    • Sesti, G.1    Marini, M.A.2    Cardellini, M.3    Sciacqua, A.4    Frontoni, S.5    Andreozzi, F.6
  • 36
    • 0035119361 scopus 로고    scopus 로고
    • Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: Emerging insights from gene expression patterns, transgenic and gene ablation studies
    • Clatworthy JP, Subramanian V. Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies. Mech Dev 2001;101:3-9. http://dx.doi.org/10.1016/S0925-4773-(00)00557-8.
    • (2001) Mech Dev , vol.101 , pp. 3-9
    • Clatworthy, J.P.1    Subramanian, V.2
  • 37
    • 34447340935 scopus 로고    scopus 로고
    • TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: A global meta-analysis
    • Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med (Berl) 2007;85:777-82. http://dx.doi.org/10.1007/s00109-007-0203-4.
    • (2007) J Mol Med (Berl) , vol.85 , pp. 777-782
    • Cauchi, S.1    El Achhab, Y.2    Choquet, H.3    Dina, C.4    Krempler, F.5    Weitgasser, R.6
  • 38
    • 61849101938 scopus 로고    scopus 로고
    • Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: A large Human Genome Epidemiology (HuGE) review and meta-analysis
    • Tong Y, Lin Y, Zhang Y, Yang J, Liu H, Zhang B. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009;10:15. http://dx.doi.org/10.1186/1471-2350-10-15.
    • (2009) BMC Med Genet , vol.10 , pp. 15
    • Tong, Y.1    Lin, Y.2    Zhang, Y.3    Yang, J.4    Liu, H.5    Zhang, B.6
  • 39
    • 78649693563 scopus 로고    scopus 로고
    • Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes
    • Schroner Z, Javorsky M, Tkacova R, Klimcakova L, Dobrikova M, Habalova V, et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:89-91. http://dx.doi.org/10.1111/j.1463-1326.2010.01324.x.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 89-91
    • Schroner, Z.1    Javorsky, M.2    Tkacova, R.3    Klimcakova, L.4    Dobrikova, M.5    Habalova, V.6
  • 40
    • 34547585382 scopus 로고    scopus 로고
    • Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study
    • Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007;56:2178-82. http://dx.doi.org/10.2337/db07-0440.
    • (2007) Diabetes , vol.56 , pp. 2178-2182
    • Pearson, E.R.1    Donnelly, L.A.2    Kimber, C.3    Whitley, A.4    Doney, A.S.5    McCarthy, M.I.6
  • 41
    • 79951960556 scopus 로고    scopus 로고
    • TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes
    • Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011;12:30. http://dx.doi.org/10.1186/1471-2350-12-30.
    • (2011) BMC Med Genet , vol.12 , pp. 30
    • Holstein, A.1    Hahn, M.2    Korner, A.3    Stumvoll, M.4    Kovacs, P.5
  • 42
    • 38349103468 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus
    • Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008;83:288-92. http://dx.doi.org/10.1038/sj.clpt.6100273.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 288-292
    • Becker, M.L.1    Visser, L.E.2    Trienekens, P.H.3    Hofman, A.4    van Schaik, R.H.5    Stricker, B.H.6
  • 43
    • 70649097093 scopus 로고    scopus 로고
    • Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
    • Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10:1781-7. http://dx.doi.org/10.2217/pgs.09.96.
    • (2009) Pharmacogenomics , vol.10 , pp. 1781-1787
    • Ragia, G.1    Petridis, I.2    Tavridou, A.3    Christakidis, D.4    Manolopoulos, V.G.5
  • 44
    • 78649799516 scopus 로고    scopus 로고
    • Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
    • Semiz S, Dujic T, Ostanek B, Prnjavorac B, Bego T, Malenica M, et al. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J Basic Med Sci 2010;10:287-91.
    • (2010) Bosn J Basic Med Sci , vol.10 , pp. 287-291
    • Semiz, S.1    Dujic, T.2    Ostanek, B.3    Prnjavorac, B.4    Bego, T.5    Malenica, M.6
  • 45
    • 21744439005 scopus 로고    scopus 로고
    • Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents
    • Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmoller J, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005;60:103-6. http://dx.doi.org/10.1111/j.1365-2125.2005.02379.x.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 103-106
    • Holstein, A.1    Plaschke, A.2    Ptak, M.3    Egberts, E.H.4    El-Din, J.5    Brockmoller, J.6
  • 47
    • 77957274993 scopus 로고    scopus 로고
    • Pharmacogenetics of Anti-Diabetes Drugs
    • Distefano JK, Watanabe RM. Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals (Basel) 2010;3:2610-46. http://dx.doi.org/10.3390/ph3082610.
    • (2010) Pharmaceuticals (Basel) , vol.3 , pp. 2610-2646
    • Distefano, J.K.1    Watanabe, R.M.2
  • 48
    • 0036231580 scopus 로고    scopus 로고
    • Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
    • Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002;71:286-96. http://dx.doi.org/10.1067/mcp.2002.122476.
    • (2002) Clin Pharmacol Ther , vol.71 , pp. 286-296
    • Kirchheiner, J.1    Brockmoller, J.2    Meineke, I.3    Bauer, S.4    Rohde, W.5    Meisel, C.6
  • 49
    • 0036736497 scopus 로고    scopus 로고
    • Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
    • Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-32. http://dx.doi.org/10.1067/mcp.2002.127495.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 326-332
    • Niemi, M.1    Cascorbi, I.2    Timm, R.3    Kroemer, H.K.4    Neuvonen, P.J.5    Kivisto, K.T.6
  • 50
    • 78649710075 scopus 로고    scopus 로고
    • Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus
    • Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics 2010;11:1517-23. http://dx.doi.org/10.2217/pgs.10.121.
    • (2010) Pharmacogenomics , vol.11 , pp. 1517-1523
    • Swen, J.J.1    Wessels, J.A.2    Krabben, A.3    Assendelft, W.J.4    Guchelaar, H.J.5
  • 51
    • 72849111539 scopus 로고    scopus 로고
    • Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: A Go-DARTS study
    • Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2010;87:52-6. http://dx.doi.org/10.1038/clpt.2009.176.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 52-56
    • Zhou, K.1    Donnelly, L.2    Burch, L.3    Tavendale, R.4    Doney, A.S.5    Leese, G.6
  • 52
    • 34548316586 scopus 로고    scopus 로고
    • Thiazolidinediones and their fluid-related adverse effects: Facts, fiction and putative management strategies
    • Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30:741-53. http://dx.doi.org/10.2165/00002018-200730090-00002.
    • (2007) Drug Saf , vol.30 , pp. 741-753
    • Karalliedde, J.1    Buckingham, R.E.2
  • 53
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. http://dx.doi.org/10.1056/NEJMoa072761.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 54
    • 84870746928 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: A meta-analysis of retrospective cohort studies
    • Chen X, Yang L, Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J (Engl) 2012;125:4301-6.
    • (2012) Chin Med J (Engl) , vol.125 , pp. 4301-4306
    • Chen, X.1    Yang, L.2    Zhai, S.D.3
  • 55
    • 83055198551 scopus 로고    scopus 로고
    • Pioglitazone is a valid alternative to rosiglitazone
    • Derosa G. Pioglitazone is a valid alternative to rosiglitazone. Am J Cardiovasc Drugs 2011;11:357-62. http://dx.doi.org/10.2165/11595990-000000000-00000.
    • (2011) Am J Cardiovasc Drugs , vol.11 , pp. 357-362
    • Derosa, G.1
  • 56
    • 79955427509 scopus 로고    scopus 로고
    • The safety of thiazolidinediones
    • Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011;10:419-28. http://dx.doi.org/10.1517/14740 338.2011.534982.
    • (2011) Expert Opin Drug Saf , vol.10 , pp. 419-428
    • Tolman, K.G.1
  • 57
    • 0036959197 scopus 로고    scopus 로고
    • Pioglitazone: Cardiovascular effects in prediabetic patients
    • Mizushige K, Tsuji T, Noma T. Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovasc Drug Rev 2002;20:329-40. http://dx.doi.org/10.1111/j.1527-3466.2002.tb00100.x.
    • (2002) Cardiovasc Drug Rev , vol.20 , pp. 329-340
    • Mizushige, K.1    Tsuji, T.2    Noma, T.3
  • 58
    • 84866463599 scopus 로고    scopus 로고
    • Meta-analysis confirms raised risk of bladder cancer from pioglitazone
    • Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ 2012;345:e4541. http://dx.doi.org/10.1136/bmj.e4541.
    • (2012) BMJ , vol.345
    • Kermode-Scott, B.1
  • 59
    • 84863718935 scopus 로고    scopus 로고
    • Bladder cancer: Pioglitazone increases risk of bladder cancer
    • Clyne M. Bladder cancer: Pioglitazone increases risk of bladder cancer. Nat Rev Urol 2012;9:353. http://dx.doi.org/10.1038/nrurol.2012.131.
    • (2012) Nat Rev Urol , vol.9 , pp. 353
    • Clyne, M.1
  • 60
    • 84865858873 scopus 로고    scopus 로고
    • Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis
    • Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-83. http://dx.doi.org/10.1503/cmaj.112102.
    • (2012) CMAJ , vol.184
    • Colmers, I.N.1    Bowker, S.L.2    Majumdar, S.R.3    Johnson, J.A.4
  • 62
    • 0033599038 scopus 로고    scopus 로고
    • Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
    • Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-3.
    • (1999) Nature , vol.402 , pp. 880-883
    • Barroso, I.1    Gurnell, M.2    Crowley, V.E.3    Agostini, M.4    Schwabe, J.W.5    Soos, M.A.6
  • 63
    • 23444457610 scopus 로고    scopus 로고
    • Effects of Pro12Ala polymorphism of peroxisome proliferatoractivated receptor gamma2 gene on rosiglitazone response in type 2 diabetes
    • Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, et al. Effects of Pro12Ala polymorphism of peroxisome proliferatoractivated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005;78:202-8. http://dx.doi.org/10.1016/j.clpt.2005.04.013.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 202-208
    • Kang, E.S.1    Park, S.Y.2    Kim, H.J.3    Kim, C.S.4    Ahn, C.W.5    Cha, B.S.6
  • 64
    • 78650571748 scopus 로고    scopus 로고
    • Effects of the peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus
    • Zhang KH, Huang Q, Dai XP, Yin JY, Zhang W, Zhou G, et al. Effects of the peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. J Clin Pharmacol 2010;50:1022-30. http://dx.doi.org/10.1177/0091270009355159.
    • (2010) J Clin Pharmacol , vol.50 , pp. 1022-1030
    • Zhang, K.H.1    Huang, Q.2    Dai, X.P.3    Yin, J.Y.4    Zhang, W.5    Zhou, G.6
  • 65
    • 74749093514 scopus 로고    scopus 로고
    • A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes
    • Makino H, Shimizu I, Murao S, Kondo S, Tabara Y, Fujiyama M, et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes. Endocr J 2009;56:1049-58. http://dx.doi.org/10.1507/endocrj.K08E-320.
    • (2009) Endocr J , vol.56 , pp. 1049-1058
    • Makino, H.1    Shimizu, I.2    Murao, S.3    Kondo, S.4    Tabara, Y.5    Fujiyama, M.6
  • 66
    • 43549096615 scopus 로고    scopus 로고
    • The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients
    • Sun H, Gong ZC, Yin JY, Liu HL, Liu YZ, Guo ZW, et al. The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients. Br J Clin Pharmacol 2008;65:917-26. http://dx.doi.org/10.1111/j.1365-2125.2008.03145.x.
    • (2008) Br J Clin Pharmacol , vol.65 , pp. 917-926
    • Sun, H.1    Gong, Z.C.2    Yin, J.Y.3    Liu, H.L.4    Liu, Y.Z.5    Guo, Z.W.6
  • 67
    • 44449136358 scopus 로고    scopus 로고
    • Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes
    • Liu HL, Lin YG, Wu J, Sun H, Gong ZC, Hu PC, et al. Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes. Eur J Clin Pharmacol 2008;64:663-71. http://dx.doi.org/10.1007/s00228-008-0483-9.
    • (2008) Eur J Clin Pharmacol , vol.64 , pp. 663-671
    • Liu, H.L.1    Lin, Y.G.2    Wu, J.3    Sun, H.4    Gong, Z.C.5    Hu, P.C.6
  • 68
    • 81055156102 scopus 로고    scopus 로고
    • Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes
    • Chang TJ, Liu PH, Liang YC, Chang YC, Jiang YD, Li HY, et al. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes. Pharmacogenet Genomics 2011;21:829-36. http://dx.doi.org/10.1097/FPC.0b013e32834bfff1.
    • (2011) Pharmacogenet Genomics , vol.21 , pp. 829-836
    • Chang, T.J.1    Liu, P.H.2    Liang, Y.C.3    Chang, Y.C.4    Jiang, Y.D.5    Li, H.Y.6
  • 69
    • 33745703773 scopus 로고    scopus 로고
    • Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: Potential for interactions with CYP2C8 inhibitors
    • Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44-51. http://dx.doi.org/10.1111/j.1742-7843.2006.pto_437.x.
    • (2006) Basic Clin Pharmacol Toxicol , vol.99 , pp. 44-51
    • Jaakkola, T.1    Laitila, J.2    Neuvonen, P.J.3    Backman, J.T.4
  • 70
    • 29244482237 scopus 로고    scopus 로고
    • Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance
    • Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005;44:1209-25. http://dx.doi.org/10.2165/00003088-200544120-00002.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 1209-1225
    • Kirchheiner, J.1    Roots, I.2    Goldammer, M.3    Rosenkranz, B.4    Brockmoller, J.5
  • 71
  • 72
    • 84855185039 scopus 로고    scopus 로고
    • Standards of medical care in diabetes--2012
    • Standards of medical care in diabetes--2012. Diabetes Care 2012;35 Suppl 1:S11-63. http://dx.doi.org/10.2337/dc12-s011.
    • (2012) Diabetes Care , vol.35 , Issue.SUPPL. 1
  • 74
    • 0034773404 scopus 로고    scopus 로고
    • Role of AMP-activated protein kinase in mechanism of metformin action
    • Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
    • (2001) J Clin Invest , vol.108 , pp. 1167-1174
    • Zhou, G.1    Myers, R.2    Li, Y.3    Chen, Y.4    Shen, X.5    Fenyk-Melody, J.6
  • 75
    • 0034614420 scopus 로고    scopus 로고
    • Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I
    • El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223-8. http://dx.doi.org/10.1074/jbc.275.1.223.
    • (2000) J Biol Chem , vol.275 , pp. 223-228
    • El-Mir, M.Y.1    Nogueira, V.2    Fontaine, E.3    Averet, N.4    Rigoulet, M.5    Leverve, X.6
  • 76
    • 0034659785 scopus 로고    scopus 로고
    • Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
    • Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348 Pt 3:607-14. http://dx.doi.org/10.1042/0264-6021:3480607.
    • (2000) Biochem J , vol.348 , Issue.PART 3 , pp. 607-614
    • Owen, M.R.1    Doran, E.2    Halestrap, A.P.3
  • 78
    • 28844433635 scopus 로고    scopus 로고
    • The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin
    • Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6. http://dx.doi.org/10.1126/science.1120781.
    • (2005) Science , vol.310 , pp. 1642-1646
    • Shaw, R.J.1    Lamia, K.A.2    Vasquez, D.3    Koo, S.H.4    Bardeesy, N.5    Depinho, R.A.6
  • 79
    • 77954933558 scopus 로고    scopus 로고
    • Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
    • Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69. http://dx.doi.org/10.1172/JCI40671.
    • (2010) J Clin Invest , vol.120 , pp. 2355-2369
    • Foretz, M.1    Hebrard, S.2    Leclerc, J.3    Zarrinpashneh, E.4    Soty, M.5    Mithieux, G.6
  • 80
    • 0038727578 scopus 로고    scopus 로고
    • Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects
    • Robert F, Fendri S, Hary L, Lacroix C, Andrejak M, Lalau JD. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 2003;29:279-83. http://dx.doi.org/10.1016/S1262-3636-(07)70037-X.
    • (2003) Diabetes Metab , vol.29 , pp. 279-283
    • Robert, F.1    Fendri, S.2    Hary, L.3    Lacroix, C.4    Andrejak, M.5    Lalau, J.D.6
  • 81
    • 0141649391 scopus 로고    scopus 로고
    • Estimating the contribution of genes and environment to variation in renal drug clearance
    • Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003;13:581-4. http://dx.doi.org/10.1097/00008571-200309000-00007.
    • (2003) Pharmacogenetics , vol.13 , pp. 581-584
    • Leabman, M.K.1    Giacomini, K.M.2
  • 82
    • 31344468048 scopus 로고    scopus 로고
    • Variability in renal clearance of substrates for renal transporters in chinese subjects
    • Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in chinese subjects. J Clin Pharmacol 2006;46:157-63. http://dx.doi.org/10.1177/0091270005283838.
    • (2006) J Clin Pharmacol , vol.46 , pp. 157-163
    • Yin, O.Q.1    Tomlinson, B.2    Chow, M.S.3
  • 84
    • 34748922537 scopus 로고    scopus 로고
    • Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine
    • Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007;35:1956-62. http://dx.doi.org/10.1124/dmd.107.015495.
    • (2007) Drug Metab Dispos , vol.35 , pp. 1956-1962
    • Zhou, M.1    Xia, L.2    Wang, J.3
  • 85
    • 0036070666 scopus 로고    scopus 로고
    • Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
    • Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-5. http://dx.doi.org/10.1124/jpet.102.034140.
    • (2002) J Pharmacol Exp Ther , vol.302 , pp. 510-515
    • Wang, D.S.1    Jonker, J.W.2    Kato, Y.3    Kusuhara, H.4    Schinkel, A.H.5    Sugiyama, Y.6
  • 86
    • 16844384592 scopus 로고    scopus 로고
    • Metformin transport by renal basolateral organic cation transporter hOCT2
    • Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005;22:255-9. http://dx.doi.org/10.1007/s11095-004-1193-3.
    • (2005) Pharm Res , vol.22 , pp. 255-259
    • Kimura, N.1    Okuda, M.2    Inui, K.3
  • 87
    • 29144523534 scopus 로고    scopus 로고
    • A human transporter protein that mediates the final excretion step for toxic organic cations
    • Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 2005;102:17923-8. http://dx.doi.org/10.1073/pnas.0506483102.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 17923-17928
    • Otsuka, M.1    Matsumoto, T.2    Morimoto, R.3    Arioka, S.4    Omote, H.5    Moriyama, Y.6
  • 88
    • 33746548445 scopus 로고    scopus 로고
    • Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2
    • Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127-35. http://dx.doi.org/10.1681/ASN.2006030205.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 2127-2135
    • Masuda, S.1    Terada, T.2    Yonezawa, A.3    Tanihara, Y.4    Kishimoto, K.5    Katsura, T.6
  • 89
    • 79956333806 scopus 로고    scopus 로고
    • Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects
    • Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89:837-44. http://dx.doi.org/10.1038/clpt.2011.36.
    • (2011) Clin Pharmacol Ther , vol.89 , pp. 837-844
    • Kusuhara, H.1    Ito, S.2    Kumagai, Y.3    Jiang, M.4    Shiroshita, T.5    Moriyama, Y.6
  • 90
    • 33845405222 scopus 로고    scopus 로고
    • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. http://dx.doi.org/10.1056/NEJMoa066224.
    • (2006) N Engl J Med , vol.355 , pp. 2427-2443
    • Kahn, S.E.1    Haffner, S.M.2    Heise, M.A.3    Herman, W.H.4    Holman, R.R.5    Jones, N.P.6
  • 91
    • 34248156160 scopus 로고    scopus 로고
    • Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
    • Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-31. http://dx.doi.org/10.1172/JCI30558.
    • (2007) J Clin Invest , vol.117 , pp. 1422-1431
    • Shu, Y.1    Sheardown, S.A.2    Brown, C.3    Owen, R.P.4    Zhang, S.5    Castro, R.A.6
  • 92
    • 38349085099 scopus 로고    scopus 로고
    • Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics
    • Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83:273-80. http://dx.doi.org/10.1038/sj.clpt.6100275.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 273-280
    • Shu, Y.1    Brown, C.2    Castro, R.A.3    Shi, R.J.4    Lin, E.T.5    Owen, R.P.6
  • 93
    • 69449098951 scopus 로고    scopus 로고
    • The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin
    • Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306. http://dx.doi.org/10.1038/clpt.2009.92.
    • (2009) Clin Pharmacol Ther , vol.86 , pp. 299-306
    • Tzvetkov, M.V.1    Vormfelde, S.V.2    Balen, D.3    Meineke, I.4    Schmidt, T.5    Sehrt, D.6
  • 94
    • 66649121405 scopus 로고    scopus 로고
    • Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study
    • Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009;58:1434-9. http://dx.doi.org/10.2337/db08-0896.
    • (2009) Diabetes , vol.58 , pp. 1434-1439
    • Zhou, K.1    Donnelly, L.A.2    Kimber, C.H.3    Donnan, P.T.4    Doney, A.S.5    Leese, G.6
  • 95
    • 67849116869 scopus 로고    scopus 로고
    • Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
    • Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009;9:242-7. http://dx.doi.org/10.1038/tpj.2009.15.
    • (2009) Pharmacogenomics J , vol.9 , pp. 242-247
    • Becker, M.L.1    Visser, L.E.2    van Schaik, R.H.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.6
  • 96
    • 81055140250 scopus 로고    scopus 로고
    • The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
    • Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21:837-50. http://dx.doi.org/10.1097/FPC.0b013e32834c0010.
    • (2011) Pharmacogenet Genomics , vol.21 , pp. 837-850
    • Christensen, M.M.1    Brasch-Andersen, C.2    Green, H.3    Nielsen, F.4    Damkier, P.5    Beck-Nielsen, H.6
  • 97
    • 84864950319 scopus 로고    scopus 로고
    • Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients
    • Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics 2012;22:659-66. http://dx.doi.org/10.1097/FPC.0b013e3283561666.
    • (2012) Pharmacogenet Genomics , vol.22 , pp. 659-666
    • Tarasova, L.1    Kalnina, I.2    Geldnere, K.3    Bumbure, A.4    Ritenberga, R.5    Nikitina-Zake, L.6
  • 98
    • 0028158709 scopus 로고
    • Accumulation of metformin by tissues of the normal and diabetic mouse
    • Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994;24:49-57. http://dx.doi.org/10.3109/00498259409043220.
    • (1994) Xenobiotica , vol.24 , pp. 49-57
    • Wilcock, C.1    Bailey, C.J.2
  • 99
    • 27744454598 scopus 로고    scopus 로고
    • Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)
    • Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005;70:1851-60. http://dx.doi.org/10.1016/j.bcp.2005.09.011.
    • (2005) Biochem Pharmacol , vol.70 , pp. 1851-1860
    • Muller, J.1    Lips, K.S.2    Metzner, L.3    Neubert, R.H.4    Koepsell, H.5    Brandsch, M.6
  • 100
    • 54249106729 scopus 로고    scopus 로고
    • Genetic variants of the organic cation transporter 2 influence the disposition of metformin
    • Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008;84:559-62. http://dx.doi.org/10.1038/clpt.2008.61.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 559-562
    • Song, I.S.1    Shin, H.J.2    Shim, E.J.3    Jung, I.S.4    Kim, W.Y.5    Shon, J.H.6
  • 101
    • 53049095113 scopus 로고    scopus 로고
    • OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine
    • Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008;18:637-45. http://dx.doi.org/10.1097/FPC.0b013e328302cd41.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 637-645
    • Wang, Z.J.1    Yin, O.Q.2    Tomlinson, B.3    Chow, M.S.4
  • 102
    • 67651235787 scopus 로고    scopus 로고
    • Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
    • Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009;19:497-504. http://dx.doi.org/10.1097/FPC.0b013e32832cc7e9.
    • (2009) Pharmacogenet Genomics , vol.19 , pp. 497-504
    • Chen, Y.1    Li, S.2    Brown, C.3    Cheatham, S.4    Castro, R.A.5    Leabman, M.K.6
  • 103
    • 62749133967 scopus 로고    scopus 로고
    • Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study
    • Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009;58:745-9. http://dx.doi.org/10.2337/db08-1028.
    • (2009) Diabetes , vol.58 , pp. 745-749
    • Becker, M.L.1    Visser, L.E.2    van Schaik, R.H.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.6
  • 104
    • 77957601724 scopus 로고    scopus 로고
    • Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program
    • Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010;59:2672-81. http://dx.doi.org/10.2337/db10-0543.
    • (2010) Diabetes , vol.59 , pp. 2672-2681
    • Jablonski, K.A.1    McAteer, J.B.2    de Bakker, P.I.3    Franks, P.W.4    Pollin, T.I.5    Hanson, R.L.6
  • 105
    • 80054970528 scopus 로고    scopus 로고
    • A common 5'-UTR variant in MATE2-K is associated with poor response to metformin
    • Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011;90:674-84. http://dx.doi.org/10.1038/clpt.2011.165.
    • (2011) Clin Pharmacol Ther , vol.90 , pp. 674-684
    • Choi, J.H.1    Yee, S.W.2    Ramirez, A.H.3    Morrissey, K.M.4    Jang, G.H.5    Joski, P.J.6
  • 106
    • 78049298630 scopus 로고    scopus 로고
    • Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin
    • Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010;20:687-99. http://dx.doi.org/10.1097/FPC.0b013e32833fe789.
    • (2010) Pharmacogenet Genomics , vol.20 , pp. 687-699
    • Chen, L.1    Pawlikowski, B.2    Schlessinger, A.3    More, S.S.4    Stryke, D.5    Johns, S.J.6
  • 107
    • 79251612707 scopus 로고    scopus 로고
    • Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
    • Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117-20. http://dx.doi.org/10.1038/ng.735.
    • (2011) Nat Genet , vol.43 , pp. 117-120
    • Zhou, K.1    Bellenguez, C.2    Spencer, C.C.3    Bennett, A.J.4    Coleman, R.L.5    Tavendale, R.6
  • 108
    • 33845986742 scopus 로고    scopus 로고
    • Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex
    • Yan FF, Casey J, Shyng SL. Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. J Biol Chem 2006;281:33403-13. http://dx.doi.org/10.1074/jbc.M605195200.
    • (2006) J Biol Chem , vol.281 , pp. 33403-33413
    • Yan, F.F.1    Casey, J.2    Shyng, S.L.3
  • 109
    • 0021369614 scopus 로고
    • Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl] benzoic acids
    • Brown GR, Foubister AJ. Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl] benzoic acids. J Med Chem 1984;27:79-81. http://dx.doi.org/10.1021/jm00367a016.
    • (1984) J Med Chem , vol.27 , pp. 79-81
    • Brown, G.R.1    Foubister, A.J.2
  • 110
    • 0031892659 scopus 로고    scopus 로고
    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
    • Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345-51. http://dx.doi.org/10.2337/diabetes.47.3.345.
    • (1998) Diabetes , vol.47 , pp. 345-351
    • Fuhlendorff, J.1    Rorsman, P.2    Kofod, H.3    Brand, C.L.4    Rolin, B.5    Mackay, P.6
  • 111
    • 56549086849 scopus 로고    scopus 로고
    • The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
    • Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008;66:818-25. http://dx.doi.org/10.1111/j.1365-2125.2008.03287.x.
    • (2008) Br J Clin Pharmacol , vol.66 , pp. 818-825
    • Kalliokoski, A.1    Neuvonen, M.2    Neuvonen, P.J.3    Niemi, M.4
  • 112
    • 33749985427 scopus 로고    scopus 로고
    • Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide
    • Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006;62:567-72. http://dx.doi.org/10.1111/j.1365-2125.2006.02686.x.
    • (2006) Br J Clin Pharmacol , vol.62 , pp. 567-572
    • Zhang, W.1    He, Y.J.2    Han, C.T.3    Liu, Z.Q.4    Li, Q.5    Fan, L.6
  • 113
    • 39149108768 scopus 로고    scopus 로고
    • Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    • Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008;48:311-21. http://dx.doi.org/10.1177/0091270007311569.
    • (2008) J Clin Pharmacol , vol.48 , pp. 311-321
    • Kalliokoski, A.1    Neuvonen, M.2    Neuvonen, P.J.3    Niemi, M.4
  • 114
    • 56149115550 scopus 로고    scopus 로고
    • Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    • Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 2008;18:937-42. http://dx.doi.org/10.1097/FPC.0b013e32830d733e.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 937-942
    • Kalliokoski, A.1    Backman, J.T.2    Neuvonen, P.J.3    Niemi, M.4
  • 115
    • 84877147862 scopus 로고    scopus 로고
    • Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers
    • Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou HH. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol 2013;69:407-13. http://dx.doi.org/10.1007/s00228-012-1364-9.
    • (2013) Eur J Clin Pharmacol , vol.69 , pp. 407-413
    • Cheng, Y.1    Wang, G.2    Zhang, W.3    Fan, L.4    Chen, Y.5    Zhou, H.H.6
  • 116
    • 0042318871 scopus 로고    scopus 로고
    • CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
    • Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003;56:305-14. http://dx.doi.org/10.1046/j.0306-5251.2003.01862.x.
    • (2003) Br J Clin Pharmacol , vol.56 , pp. 305-314
    • Bidstrup, T.B.1    Bjornsdottir, I.2    Sidelmann, U.G.3    Thomsen, M.S.4    Hansen, K.T.5
  • 117
    • 79955017557 scopus 로고    scopus 로고
    • Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide
    • Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 2011;39:927-32. http://dx.doi.org/10.1124/dmd.110.036921.
    • (2011) Drug Metab Dispos , vol.39 , pp. 927-932
    • Tomalik-Scharte, D.1    Fuhr, U.2    Hellmich, M.3    Frank, D.4    Doroshyenko, O.5    Jetter, A.6
  • 118
    • 84862803165 scopus 로고    scopus 로고
    • The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers
    • Xiang Q, Cui YM, Zhao X, Yan L, Zhou Y. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. Pharmacology 2012;89:105-10. http://dx.doi.org/10.1159/000336345.
    • (2012) Pharmacology , vol.89 , pp. 105-110
    • Xiang, Q.1    Cui, Y.M.2    Zhao, X.3    Yan, L.4    Zhou, Y.5
  • 119
    • 84860234285 scopus 로고    scopus 로고
    • KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients
    • Dai XP, Huang Q, Yin JY, Guo Y, Gong ZC, Lei MX, et al. KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients. Clin Exp Pharmacol Physiol 2012;39:462-8. http://dx.doi.org/10.1111/j.1440-1681.2012.05701.x.
    • (2012) Clin Exp Pharmacol Physiol , vol.39 , pp. 462-468
    • Dai, X.P.1    Huang, Q.2    Yin, J.Y.3    Guo, Y.4    Gong, Z.C.5    Lei, M.X.6
  • 120
    • 50449085998 scopus 로고    scopus 로고
    • Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus
    • Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008;40:1092-7. http://dx.doi.org/10.1038/ng.207.
    • (2008) Nat Genet , vol.40 , pp. 1092-1097
    • Yasuda, K.1    Miyake, K.2    Horikawa, Y.3    Hara, K.4    Osawa, H.5    Furuta, H.6
  • 121
    • 79951814433 scopus 로고    scopus 로고
    • Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes
    • Yu W, Hu C, Zhang R, Wang C, Qin W, Lu J, et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2011;89:437-42. http://dx.doi.org/10.1038/clpt.2010.351.
    • (2011) Clin Pharmacol Ther , vol.89 , pp. 437-442
    • Yu, W.1    Hu, C.2    Zhang, R.3    Wang, C.4    Qin, W.5    Lu, J.6
  • 122
    • 78649328506 scopus 로고    scopus 로고
    • Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients
    • Huang Q, Yin JY, Dai XP, Wu J, Chen X, Deng CS, et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol 2010;66:1207-15. http://dx.doi.org/10.1007/s00228-010-0882-6.
    • (2010) Eur J Clin Pharmacol , vol.66 , pp. 1207-1215
    • Huang, Q.1    Yin, J.Y.2    Dai, X.P.3    Wu, J.4    Chen, X.5    Deng, C.S.6
  • 123
    • 77149143848 scopus 로고    scopus 로고
    • KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes
    • Yu M, Xu XJ, Yin JY, Wu J, Chen X, Gong ZC, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2010;87:330-5. http://dx.doi.org/10.1038/clpt.2009.242.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 330-335
    • Yu, M.1    Xu, X.J.2    Yin, J.Y.3    Wu, J.4    Chen, X.5    Gong, Z.C.6
  • 124
    • 79960729009 scopus 로고    scopus 로고
    • NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus
    • Sheng FF, Dai XP, Qu J, Lei GH, Lu HB, Wu J, et al. NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 2011;38:550-4. http://dx.doi.org/10.1111/j.1440-1681.2011.05548.x.
    • (2011) Clin Exp Pharmacol Physiol , vol.38 , pp. 550-554
    • Sheng, F.F.1    Dai, X.P.2    Qu, J.3    Lei, G.H.4    Lu, H.B.5    Wu, J.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.